Compare AJANTA PHARMA with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs TTK HEALTHCARE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA TTK HEALTHCARE AJANTA PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 22.2 18.3 121.2% View Chart
P/BV x 3.8 1.5 260.7% View Chart
Dividend Yield % 0.9 1.1 87.5%  

Financials

 AJANTA PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
TTK HEALTHCARE
Mar-19
AJANTA PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,4221,215 117.0%   
Low Rs898610 147.1%   
Sales per share (Unadj.) Rs233.5444.4 52.6%  
Earnings per share (Unadj.) Rs44.017.2 254.9%  
Cash flow per share (Unadj.) Rs52.227.6 188.8%  
Dividends per share (Unadj.) Rs9.005.00 180.0%  
Dividend yield (eoy) %0.80.5 141.6%  
Book value per share (Unadj.) Rs255.1177.9 143.4%  
Shares outstanding (eoy) m88.0214.13 622.9%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.02.1 241.8%   
Avg P/E ratio x26.452.9 49.9%  
P/CF ratio (eoy) x22.233.0 67.3%  
Price / Book Value ratio x4.55.1 88.7%  
Dividend payout %20.529.0 70.6%   
Avg Mkt Cap Rs m102,08112,894 791.7%   
No. of employees `0006.82.3 294.1%   
Total wages/salary Rs m4,3071,307 329.5%   
Avg. sales/employee Rs Th3,022.62,715.7 111.3%   
Avg. wages/employee Rs Th633.4565.3 112.0%   
Avg. net profit/employee Rs Th569.1105.4 539.9%   
INCOME DATA
Net Sales Rs m20,5546,279 327.4%  
Other income Rs m21178 272.0%   
Total revenues Rs m20,7656,356 326.7%   
Gross profit Rs m5,664496 1,142.9%  
Depreciation Rs m721147 491.3%   
Interest Rs m1234 34.3%   
Profit before tax Rs m5,143393 1,309.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273149 854.9%   
Profit after tax Rs m3,870244 1,587.9%  
Gross profit margin %27.67.9 349.1%  
Effective tax rate %24.837.9 65.3%   
Net profit margin %18.83.9 485.1%  
BALANCE SHEET DATA
Current assets Rs m11,8122,717 434.7%   
Current liabilities Rs m3,7761,571 240.4%   
Net working cap to sales %39.118.3 214.1%  
Current ratio x3.11.7 180.8%  
Inventory Days Days7732 240.6%  
Debtors Days Days8247 174.9%  
Net fixed assets Rs m14,398991 1,452.9%   
Share capital Rs m175141 124.1%   
"Free" reserves Rs m22,2772,373 938.8%   
Net worth Rs m22,4522,514 893.0%   
Long term debt Rs m73 194.1%   
Total assets Rs m26,9624,158 648.4%  
Interest coverage x444.312.6 3,522.2%   
Debt to equity ratio x00 21.7%  
Sales to assets ratio x0.81.5 50.5%   
Return on assets %14.46.7 215.7%  
Return on equity %17.29.7 177.8%  
Return on capital %23.016.9 135.5%  
Exports to sales %03.6 0.0%   
Imports to sales %00.5 0.0%   
Exports (fob) Rs mNA225 0.0%   
Imports (cif) Rs mNA31 0.0%   
Fx inflow Rs m10,682225 4,743.2%   
Fx outflow Rs m2,10271 2,955.8%   
Net fx Rs m8,580154 5,568.0%   
CASH FLOW
From Operations Rs m3,748173 2,165.1%  
From Investments Rs m-2,22897 -2,308.8%  
From Financial Activity Rs m-1,475-307 479.9%  
Net Cashflow Rs m45-38 -119.9%  

Share Holding

Indian Promoters % 73.8 65.4 112.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 3.7 41.9%  
FIIs % 7.6 5.2 146.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 25.8 65.9%  
Shareholders   20,968 12,723 164.8%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  CIPLA  TORRENT PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Higher; IT and Banking Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended higher. Benchmark Indices were highly volatile swinging between positive and negative territory.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY20); Net Profit Down 7.2% (Quarterly Result Update)

Nov 8, 2019 | Updated on Nov 8, 2019

For the quarter ended September 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 7.2% YoY). Sales on the other hand came in at Rs 6 bn (up 18.1% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 14, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS